HEMOSOL morgen Internetkonferenz mit NEWS......... - 500 Beiträge pro Seite

[Big Charly]

TORONTO, April 3 /CNW/ - Hemosol Inc. (NASDAQ: HMSL, TSE: HML) today
announced that its financial results for the three-month and year ended
December 31, 2000 will be released following the close of the U.S. financial
markets on April 5, 2001. The Company will hold a conference call to discuss
these results at 4:30p.m. Eastern time on April 5, 2001.
A live audio webcast of the conference call will be available through
www.investorlook.com. Please connect to this website at least 15 minutes prior
to the conference call to ensure adequate time for any software download that
may be needed to hear the webcast. A replay of the webcast will be available
for 30 days starting on April 6, at www.investorlook.com and www.hemosol.com.
A replay of the conference call will also be available by telephone from
approximately 6:00p.m. Eastern time on April 5 through April 9, 2001. To
access the replay, dial, 416-695-5800 or 1-800-408-3053 and enter reservation
number 737859.
Minimum requirements to listen to the live broadcast are: a computer with
speakers, the RealPlayer software, downloadable free from
www.real.com/products/player/index.html, and an active connection to the
Internet. If you experience problems listening to the broadcast, go to
www.financialdisclosure.ca and click the `test` tab.

Toronto, April 3 / Cnw / - Hemosol Inc. (Nasdaq: HMSL, TSE: HML)
heute verkündet, daß seine finanziellen Resultate das dreimonatige
und Jahr Dezember 31 beendeten, 2000 wird nach dem Abschluß der
Geldmärkte für VEREINIGTER STAATEN an April 5, 2001 freigegeben.
Die Firma hält einen Konferenzaufruf an, um diese Resultate zur
östlichen Zeit 4:30p.m. an April 5, 2001 zu behandeln. Ein
Phasenaudiowebcast des Konferenzaufrufs ist durch www.investorlook.com
vorhanden. Schließen Sie bitte an dieses website mindestens 15
Minuten vor dem Konferenzaufruf zum Sicherstellen der ausreichenden
Zeit für jedes mögliches Software-Download an, das erforderlich sein
kann, das webcast zu hören. Ein Replay an von des webcast ist für
30 vorhanden Tage, die an April 6, www.investorlook.com und
www.hemosol.com beginnen. Ein Replay bei von des Konferenzaufrufs
auch ist durch Telefon von der östlichen Zeit ungefähr 6:00p.m.
Aprils 5 bis Aprils 9, 2001 vorhanden. Den Replay, Vorwahlknopf, das
416-695-5800 oder das 1-800-408-3053 zugreifen und Reservierung Nr.
737859 eintragen. Minimale Anforderungen, zur Phasensendung zu hören
sind: ein Computer mit Lautsprecher, d RealPlayer Software,
downloadable frei von www.real.com/products/player/index.html, und ein
aktiv Anschluß zu d Internet. Wenn Sie experien

[qrzuso]

Wo steht da was von NEWS ?

[schnirchel]

Schaut mal unter Stockhouse.ca/Nasdaq nach.
Der Artikel mit Kaufempfehlungen (strong buy) ist zwar vom 28.3.01 ist aber m.M. nach lesenswert.
StockHouse International:

Company Search: Symbol
Name
for on AllUSA NASDAQ NYSE OTC:BB AMEXCanada TSE CDNX MontrealUK (LSE)Hong KongAustraliaSingaporeMalaysia


Home My Portfolio SHfn BullBoards News Releases MediaScan The Markets Feedback Help










- Site Map - - Home - About Us - Advertise - Bookstore - BullBoards - Company Profiles - Company Search - Corporate Services - IPO - Jobs @ StockHouse - MediaScan - Member Preferences - News Releases - My Portfolio - Resource Center - SHfn - The Markets


Investment
Resources


Hemosol, Inc. Snapshot | HMSL Forum | BullBoards Main


Posted By Subject Post Time (EST) Post ID


downtick (ID#: 323174) ---Strong Buy ( Target price of $ 40.00 )--- 3/30/01 21:10 3375491
« Previous Message Next Message »

For those who may have missed this article. The future looks damm good. I mean DAMM good.

Bloody Good Ratings
Wed, Mar. 28, 2001 16:37

By Crystal Quast, Canada-iNvest.com

Analyst upgrades are pouring in Wednesday morning for blood substitute maker Hemosol (HML).

Despite analysts’ rosy outlook for the company however, Hemosol shares are flat-lining. The stock closed down $0.15 at $14.20 on the Toronto Stock Exchange, and has a 52-week range of $10.25 to $25.60. The stock, which trades under the symbol (HMSL) on Nasdaq, closed at US$9.03 south of the border.

Dain Rauscher Wessels analyst Sanjiv Arora picked up coverage on Hemosol with a "buy" rating and a 12-month price target of US$13.00.

Likewise, Charles Olsziewski at UBS Warburg is calling Hemosol a "strong buy" with a slightly higher price tag of US$17. The Minneapolis-based pundit was out of town, and unavailable for comment.

Maintaining a "strong buy" rating is Wayne Schnarr at Canaccord Capital. The Toronto-based analyst has a 12-to-18 month target price of $40.

"We like the space that they`re in terms of blood substitutes. We continue to believe that hemoglobin oxygen carriers like Hemosol can still carve out a niche marketplace," says Arora.

Over 14 million transfusions take place in North America every year. Of those, 300,000 are related to coronary bypass procedures. Though Arora says Hemosol`s Hemolink blood product may occasionally be used in trauma cases, coronary surgery will be make up the heart of their sales.

Schnarr says that not only is the potential market huge, but the initial capacity of the facility that Hemosol is building is only 200,000-300,000 units annually. "That`s only 1% of the world market for red blood cells, so we`re not talking a lot of market penetration to fill up the capacity of their facility."

While Hemosol isn`t the only player in this niche market, both Arora and Schnarr believe Hemosol has a first mover advantage.

"It`s a large enough market for everyone to share," says Schnarr. "Hemosol has a chance of being there by themselves initially."

The Toronto-based firm has already received positive data from its Phase III Canadian and European trials. U.S. Phase III trials are now underway and results are expected to be released as they become available, most likely by the third quarter.

"Because you have the previous data," says Schnarr, "you have a good comfort level that you won`t get any surprises n the U.S Phase III trial."

Arora says there is no doubt that the U.S. trials will prove the efficacy of Hemolink. He says the FDA will really be looking at safety concerns. "The Phase III results in Canada look pretty positive, which would lead us to believe things will be okay. But you never know. It`s a larger trial, " states Arora. "So if anything is going to show up it`s going to show up in this trial."

Safety concerns have already waylaid one of Hemosol`s direct competitors. Alliance Pharmaceuticals (ALLP) reported a high stroke rate in its Phase III clinical results. "They`ve definitely been set back in their market development, or approval process," says Arora.

"We also think that Hemosol has a significant lead building manufacturing capacity. They`ve already broken ground and are on track to having a new manufacturing facility completed by the end of the year," Arora says.

In comparison, Biopure (BPUS) announced that it will build a manufacturing facility with annual capacity of 500,000 units of its Hemopure product in South Carolina. Ground breaking is expected to take place in the fall of 2001, with construction and FDA approval taking another 30-36 months.

"Hemosol has an 18-month, maybe longer, lead over Biopure in terms of ramping to significant manufacturing capacity," states Arora.

While these analysts agree that both companies will eventually receive FDA approval for their blood substitutes and manufacturing facilities, Biopure`s use of cow products could cause some concern for regulatory bodies and the general public.

According to Arora, Biopure has a disease-free, controlled herd that they get their blood products from. However, with all of the hype surrounding mad-cow disease, the public may have a perceptual problem with medicinal products made using cow matter.

Hemosol uses human blood for its base. While there are certainly a variety of lethal human diseases like AIDS and Hepatitis B and C that can be passed via human blood, there are also reliable methods to test for them. Not only can Hemosol test for these agents, it can also validate the process for getting rid of them by adding them into its supply and then testing for the virus`s after the process is complete.

There is currently no approved method to test for prions, the agent that causes mad-cow disease. So not only can Biopure not assure regulators that its product is virus free, it also can`t develop an approved process to take the virus out since it can`t be added into their supply in the first place. "That`s the kind of question the regulators may ask," says Schnarr. "Right now they`re relying on the fact that there has never been a confirmed case of BSE (mad-cow) in the U.S., where all of their bovine blood comes from."

"Still, I`m assuming Biopure will get there, " says Schnarr.

Northfield Laboratories (NFLD), another competitor, also uses human products to manufacture its blood substitute, but is taking longer than expected to complete its testing.

Despite the spate of competitors on its heels and regulatory hoops to jump through, both analysts like Hemosol`s future prospects.

"There`s a good balance of risks and rewards," says Schnarr.



« Previous Message Next Message »


This message has been viewed 45 times

Report a BullBoards Violation Ignore downtick Post Reply View Threads

Go to
BullBoard: Symbol Company Name
Search by
Post ID:



9 Red Flags to Help Spot Message Board Scammers | BullBoards Abbreviations




Australia Canada Hong Kong Japan Singapore UK Investment.com

Home My Portfolio SHfn BullBoards News Releases MediaScan The Markets Feedback Help

Copyright 2001 StockHouse Media Corporation. All Rights Reserved.
Disclaimer / Terms of Use - Privacy Policy Charts provided by Prophet Finance. Prophet user agreement applies.
North American quotes provided by NAQ.
Quotes Provided by S&P Comstock